Robert T Doss

Address:

1344 Hartford St, Glendale Heights, IL 60139

Phone:

6306820391

VIN:

2G2WC58C471124756

Make:

PONTIAC

Model:

GRAND PRIX

Year:

2007

US Patent:

7776605, Aug 17, 2010

Filed:

Oct 26, 2006

Appl. No.:

11/588073

Inventors:

Phillip G. Mattingly - Third Lake IL, US
Maciej Adamczyk - Gurnee IL, US
Roy Jeffrey Brashear - Mundelein IL, US
Robert C. Doss - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

G01N 31/00
G01N 33/53

US Classification:

436 8, 435 71, 435 79, 436 10, 436175, 436506, 436513, 436518, 436523, 436524, 436528, 436540

Abstract:

The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.

US Patent:

8173382, May 8, 2012

Filed:

Aug 17, 2010

Appl. No.:

12/857615

Inventors:

Phillip G. Mattingly - Third Lake IL, US
Maciej Adamczyk - Gurnee IL, US
Roy Jeffrey Brashear - Mundelein IL, US
Robert C. Doss - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

G01N 31/00
G01N 33/53

US Classification:

435 793, 435 71, 436 8, 436 10, 436175, 436506, 436518, 436523, 436524, 436528, 436540

Abstract:

The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.

US Patent:

8501420, Aug 6, 2013

Filed:

Aug 30, 2010

Appl. No.:

12/871056

Inventors:

Saul A. Datwyler - Evanston IL, US
Jessie W. Shih - Lake Forest IL, US
Robert C. Doss - Libertyville IL, US
Walter J. Keirans - Libertyville IL, US
Sudarshan Hebbar - Chicago IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

G01N 31/00

US Classification:

435 721, 435 4, 435 71, 4352879, 436501, 436518, 427287, 427337, 427338, 530300, 530350

Abstract:

The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient.

US Patent:

20070111326, May 17, 2007

Filed:

Mar 3, 2006

Appl. No.:

11/367126

Inventors:

David Sogin - Highland Park IL, US
Donald Laird - Mundelein IL, US
George Yu - Libertyville IL, US
Robert Doss - Libertyville IL, US

International Classification:

G01N 33/543

US Classification:

436518000

Abstract:

Method of measuring the quantity of a first proteinaceous specific binding partner (sbp) in a biological sample comprising detecting the binding of the first proteinaceous sbp with a labeled second proteinaceous sbp, wherein neither the first or second sbp is an antibody or fragment thereof, which is preferably a method of determining the amount of sFlt-1, particularly free sFlt-1, and the amount of PlGF, particularly free PlGF, in a sample, which is preferably used in a method of predicting risk of preeclampsia comprising comparing free PlGF to free sFlt-1.

US Patent:

20080305512, Dec 11, 2008

Filed:

Nov 2, 2007

Appl. No.:

11/934688

Inventors:

Phillip G. Mattingly - Third Lake IL, US
Maciej Adamczyk - Gurnee IL, US
Roy Jeffrey Brashear - Mundelein IL, US
Robert C. Doss - Libertyville IL, US

International Classification:

C12Q 1/28
G01N 33/564

US Classification:

435 28, 436506

Abstract:

The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.

US Patent:

20110229921, Sep 22, 2011

Filed:

Jun 9, 2010

Appl. No.:

12/796794

Inventors:

Robert C. Doss - Libertyville IL, US
Sudarshan Hebbar - Chicago IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

C12Q 1/37

US Classification:

435 23

Abstract:

A method of prognosticating cadaveric kidney transplant function in a patient; a method of prognosticating cadaveric kidney transplant function in a patient diagnosed with DGF; a method of assessing risk of DGF in a patient, who has been diagnosed with EGF; and a kit comprising at least one component for assaying urine from a patient for NGAL and instructions for assaying the urine for NGAL and assessing cadaveric kidney transplant function or risk of DGF in the patient.